Q2 2025 Capricor Therapeutics Inc Earnings Call Transcript
Key Points
- Capricor Therapeutics Inc (CAPR) has a strong cash position of approximately $122.8 million, which is expected to support operations until late 2026.
- The company has received FDA acceptance of all 483 items from their pre-license inspection, validating their manufacturing capabilities and commercial readiness.
- Capricor's exosome program has reached a significant milestone with the clearance of the IND and initiation of a phase one clinical trial for their Stealth X vaccine.
- The company is strategically investing in launch readiness activities, including physician education and market access planning, to ensure a smooth transition to commercial use if approved.
- Capricor Therapeutics Inc (CAPR) is eligible for a priority review voucher and an $80 million milestone payment from Nihon Shinyaku upon potential approval, representing significant non-dilutive capital opportunities.
- Capricor Therapeutics Inc (CAPR) received a complete response letter (CRL) from the FDA, indicating that their BLA does not meet the statutory requirements for substantial evidence of effectiveness.
- The company reported zero revenues for the second quarter and first half of 2025, compared to $4 million and $8.9 million in the same periods of 2024, respectively.
- Research and development expenses have significantly increased, reaching approximately $20.1 million in Q2 2025 compared to $11.7 million in Q2 2024.
- The net loss for the second quarter of 2025 was approximately $25.9 million, more than double the net loss of $11 million for the same period in 2024.
- Capricor Therapeutics Inc (CAPR) is facing regulatory challenges and uncertainties, particularly regarding the FDA's requirements for approval of their product candidate, Diarramycil.
Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics second-quarter 2025 conference call. (Operator Instructions) This call is being recorded on Monday, August 11, 2025.
I would now like to turn the conference over to CFO, AJ Bergmann for the forward-looking statements. Please go ahead.
Thank you and good afternoon, everyone. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include.
Statements regarding among other things, the efficacy, safety, and intended utilization of our product candidates, our future research and development plans, including our anticipated conduct and timing of pre-clinical and clinical studies, our enrollment of patients in our clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory developments involving our product candidates. Potential regulatory
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
